Cebeci Zafer, Tuncer Samuray, Kebudi Rejin
Istanbul University, Istanbul Faculty of Medicine, Ophthalmology Department, Istanbul, Turkey.
Istanbul University, Oncology Institute, Division of Pediatric Hematology-Oncology, Istanbul, Turkey.
J Ophthalmol. 2020 Jan 20;2020:8148013. doi: 10.1155/2020/8148013. eCollection 2020.
The diagnosis and management of retinoblastoma can be difficult in older children. This study reports the clinical features and long-term outcomes of such patients in a Turkish patient population.
Medical records of 18 patients, between January 1992 and December 2017, were reviewed retrospectively.
Of 298 consecutive patients with retinoblastoma, 18 (6%) were at the age of 5 years and older. The median age at diagnosis was 9 years (range, 5-18 years). Misdiagnosis was noted in 8 patients (44.4%). Treatment options included enucleation in 16 patients (88.8%), adjuvant systemic chemotherapy in 3 (16.6%), intra-arterial chemotherapy in one (5.5%), and additional orbital irradiation in one (5.5%). After a median follow-up of 97 months (range, 6-252 months), all patients survived without any recurrence.
Our series showed that 6% of patients with retinoblastoma were 5 years of age and older. Over a 15-year period, ocular salvage rate of 11.2% and survival rate of 100% were attained.
视网膜母细胞瘤在大龄儿童中的诊断和治疗颇具难度。本研究报告了土耳其患者群体中此类患者的临床特征及长期预后情况。
回顾性分析了1992年1月至2017年12月期间18例患者的病历。
在连续298例视网膜母细胞瘤患者中，18例（6%）年龄在5岁及以上。诊断时的中位年龄为9岁（范围5 - 18岁）。8例患者（44.4%）存在误诊情况。治疗方案包括16例患者（88.8%）行眼球摘除术，3例（16.6%）接受辅助全身化疗，1例（5.5%）接受动脉内化疗，1例（5.5%）接受额外的眼眶放疗。中位随访97个月（范围6 - 252个月）后，所有患者均存活且无任何复发。
我们的系列研究表明，6%的视网膜母细胞瘤患者年龄在5岁及以上。在15年期间，实现了11.2%的眼球挽救率和100%的生存率。
